Tang Capital's Concentra Biosciences offers to buy Acelyrin for $3/share, challenging planned Alumis merger. Concentra would ...
Peter Guenter to retire as healthcare CEO, replaced by Danny Bar-Zohar; Matthias Heinzel steps down from life science unit.
Lawyers for the government gave the first substantive signal that the Trump administration will continue to defend Medicare ...
A meeting of CDC vaccine advisors has been postponed, according to a senior HHS official. “The ACIP meeting will ...
Has drug giant Roche finally cracked DNA sequencing? The company has claimed it can decode the genome in as little as four ...
UnitedHealthcare offers voluntary buyouts to 30,000 employees due to low attrition and digital shift, COO Michael Baker tells ...
The European Union’s proposed ban of so-called “forever chemicals” is expected to become law this year, and investors are ...
Mother took Evrysdi for SMA before birth; baby later received Zolgensma. Dr. Richard Finkel at St. Jude led study showing no ...
Charles River Labs beats Q4 estimates, Theratechnologies resumes Egrifta SV distribution, FDA greenlights BCG alternative, ...
The proxy filing for Accolade, a healthcare navigator that connects workers to care on behalf of their employers, agreed to ...
Illumina to cut 96 San Diego jobs by April 14; Incyte partners with Genesis on AI for $30M upfront; 2048 Ventures plans $75M fund; Atai Life Sciences raises $63.2M ...
Keymed Biosciences is a prime example of a young Chinese biotech churning out pipeline candidates ripe for out-licensing to Western drugmakers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback